Exacerbations and Real-World Outcomes After Single-Inhaler Triple Therapy of Budesonide/Glycopyrrolate/Formoterol Fumarate, Among Patients with COPD: Results from the EROS (US) Study [Corrigendum]

被引：0
|
作者：
Strange, C.
Tkacz, J.
Schinkel, J.
机构：
来源：
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE | 2024年 / 19卷
关键词：
D O I：
10.2147/COPD.S484253
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页码：1799 / 1799
页数：1
相关论文
共 50 条
  • [41] First Real-World Evidence on High Dose Strength of Extrafine Single-Inhaler Triple Therapy in Asthma Patients after Three Months of Treatment TriMaximize Study
    Gessner, C.
    Bogoevska, V
    Nachtigall, D.
    Akyildiz, B.
    Martini, M.
    Wendt, A.
    Criee, C.
    PNEUMOLOGIE, 2024, 78 : S4 - S4
  • [42] Improvement of asthma control after 3 months of treatment with extrafine single-inhaler triple therapy in asthmatics: a real-world view from Germany
    Greulich, T.
    Akyildiz, B.
    Slawinska, R.
    Wendt, A.
    Bogoevska, V
    Gessner, C.
    EUROPEAN RESPIRATORY JOURNAL, 2022, 60
  • [43] Impact of extrafine single-inhaler triple therapy on treatment adherence after 6 months of treatment in asthmatics: a real-world view from Germany
    Trinkmann, Autoren F.
    Akyildiz, B.
    Grickschat, V
    Borucki, T.
    Gessner, C.
    PNEUMOLOGIE, 2023, 77 : S35 - S36
  • [44] Change in lung function after 6 months of treatment with extrafine single-inhaler triple therapy in asthmatics: a real-world view from Germany
    Gessner, C.
    Akyildiz, B.
    Wendt, A.
    Licht, B.
    Criee, C.
    PNEUMOLOGIE, 2023, 77 : S36 - S36
  • [45] Change in asthma control after 6 months of treatment with extrafine single-inhaler triple therapy in asthmatics: a real-world view from Germany
    Greulich, T.
    Akyildiz, B.
    Nachtigall, D.
    Bogoevska, V
    Gessner, C.
    PNEUMOLOGIE, 2023, 77 : S29 - S29
  • [46] Improvement of treatment adherence after 3 months of treatment with extrafine single-inhaler triple therapy in asthmatics: a real-world view from Germany
    Gessner, C.
    Akyildiz, B.
    Grickschat, V
    Borucki, T.
    Trinkmann, F.
    EUROPEAN RESPIRATORY JOURNAL, 2022, 60
  • [47] Can Patients With COPD Achieve and Maintain Disease Stability With Single-Inhaler Triple Therapy Fluticasone Furoate/Umeclidinium/Vilanterol Versus Dual Therapy Budesonide/Formoterol: A FULFIL Post Hoc Analysis
    Singh, D.
    Compton, C.
    Sharma, R.
    Sreedharan, S. K.
    Tombs, L.
    Halpin, D. M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
  • [48] Budesonide/glycopyrrolate/ formoterol fumarate metered dose inhaler, formulated using co-suspension delivery technology, improves lung function and exacerbation outcomes in patients with COPD without a recent history of exacerbations: subgroup analysis of KRONOS study
    Martinez, F. J.
    Ferguson, G. T.
    Bourne, E.
    Ballal, S.
    Darken, P.
    DeAngelis, K.
    Aurivillius, M.
    Dorinsky, P.
    Reisner, C.
    PNEUMOLOGIE, 2020, 74 : S44 - S44
  • [49] BUDESONIDE/GLYCOPYRROLATE/FORMOTEROL FUMARATE METERED DOSE INHALER, FORMULATED USING CO-SUSPENSION DELIVERY TECHNOLOGY, IMPROVES LUNG FUNCTION AND EXACERBATION OUTCOMES IN PATIENTS WITH COPD WITHOUT A RECENT HISTORY OF EXACERBATIONS: SUBGROUP ANALYSIS OF KRONOS STUDY
    Martinez, Fernando
    Ferguson, Gary
    Bourne, Eric
    Ballal, Shaila
    Darken, Patrick
    Deangelis, Kiernan
    Aurivillius, Magnus
    Dorinsky, Paul
    Reisner, Colin
    CHEST, 2019, 156 (04) : 2276A - 2277A
  • [50] Effectiveness and Patient Satisfaction with Budesonide/Formoterol Easyhaler® Among Patients with Asthma or COPD Switching from Previous Treatment: a Real-World Study of Patient-Reported Outcomes
    Gabriella Gálffy
    Maria Szilasi
    Lilla Tamási
    Pulmonary Therapy, 2019, 5 : 165 - 177
12345